Institutional
Foresite Capital Management V, LLC
CIK 0001792206
$271.0M
Reported AUM
9
Positions
Q1 2026
Period
2026-05-15
Filed
The Brief · Foresite Capital Management V, LLC · Q1 2026
AI · grounded in 13F
Foresite Capital Management V, LLC closed its position in Natera, Inc. NTRA, reducing its exposure by $15.4M. The fund established new positions in Eikon Therapeutics, Inc. EIKN for $13.9M, Pharvaris N.V. for $5.4M, and Nurix Therapeutics, Inc. NRIX for $4.1M. Additionally, the fund increased its stake in Hims & Hers Health, Inc. HIMS by 170.2%.
Portfolio · Q1 2026
Top holdings
| # | Stock | Issuer | Price | Day % | 1Y Gr. | 5Y Gr. | Value | % of book | Δ shares (QoQ) | Status |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ALMS | ALUMIS INC. | $28.95 | 9.74% | 563.92% | 122.93% | $129.9M | 47.94% | — | HELD |
| 2 | CGON | CG Oncology, Inc. | $73.03 | 5.66% | 168.57% | 58.04% | $68.0M | 25.08% | — | HELD |
| 3 | IRON | Disc Medicine, Inc. | $79.21 | 7.52% | 34.32% | -46.33% | $23.9M | 8.83% | — | HELD |
| 4 | HIMS | Hims & Hers Health, Inc. | $27.04 | 8.16% | -60.03% | 217.26% | $15.3M | 5.65% | — | HELD |
| 5 | EIKN | Eikon Therapeutics, Inc. | $9.62 | 6.77% | -33.66% | -9.07% | $14.0M | 5.15% | — | HELD |
| 6 | LYEL | Lyell Immunopharma, Inc. | $13.72 | 5.78% | 24.50% | -95.66% | $9.6M | 3.53% | — | HELD |
| 7 | PHVS | Pharvaris N.V. | $33.88 | 3.86% | 67.35% | 65.78% | $5.5M | 2.02% | — | HELD |
| 8 | NRIX | Nurix Therapeutics, Inc. | $23.58 | -0.08% | 110.51% | -27.80% | $4.1M | 1.52% | — | HELD |
| 9 | MAZE | Maze Therapeutics, Inc. | $27.63 | 1.32% | 85.44% | 125.92% | $773K | 0.29% | — | HELD |
Source: SEC EDGAR · accession 0001104659-26-062464. 13F discloses long positions only — shorts, foreign equities, and options are excluded.